GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Peptron 087010.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

93,300

-4.11%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Peptron

Its shares trade on KOSDAQ under the ticker 087010.KQ. It has been listed since 22 July 2015. In the fiscal year to 31 December 2025, it reported revenue of ₩5.63bn and a net loss of ₩13.82bn. At that date it held total assets of ₩178.98bn and shareholders' equity of ₩142.01bn.

Peptron, Inc. engages in the development of peptide-based medicines and novel drugs. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2015-07-22. The firm mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The firm also provides peptide synthesis services. The firm manufactures raw material medicines and some functional cosmetics. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
22 Jul 2015
Employees
95

Leadership

Pay as last reported

  • Ho Yil ChoiChief Executive Officer, Director
  • Sang Cheol KimChief Financial Officer, Vice President, Director
  • Min Gyu SungInternal Auditor
  • Seung Gu JangDirector
  • Hui Yong LeeDirector
  • Guk Hyeon GyungNon-Executive Independent Director
  • Yeong Go JungNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Peptron Inc develops peptide-based medicines for prostate cancer and diabetes in Daejeon.
  • The company employs 95 full-time employees specializing in Life Sciences Tools & Services.
  • Peptron offers peptide synthesis services and raw material medicines for domestic and overseas markets.

Weaknesses

  • Peptron's business is limited to peptide-based drug materials without expansion into new markets.
  • The company has no presence in the Financials or Real Estate sectors, focusing solely on Health Care.
  • Peptron's product range is restricted to prostate cancer, hyperpituitarism, and neurodegenerative disorders.

Opportunities

  • Peptron can expand peptide synthesis services to the Information Technology sector for drug development.
  • The firm may increase overseas market distribution for functional cosmetics and raw material medicines.
  • Peptron could leverage its Daejeon headquarters to attract partnerships in the Health Care industry.

Threats

  • Peptron faces competition from other Health Care firms in the Life Sciences Tools & Services sector.
  • The company's reliance on peptide-based medicines may be threatened by emerging drug technologies.
  • Peptron's domestic market focus could limit growth amid global Health Care industry trends.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.